Leprosy and international adoption: A case report and review of diagnostic and treatment dilemmas

Pediatric Infectious Disease Journal

Volumn 28, Issue 4, 2009, Pages 322-325

  King, Katherine ^a   Browning, John C ^a   Metry, Denise W ^a   Prestigiacomo, John ^b   Scollard, David ^b   Schutze, Gordon E ^a   Stryjewska, Barbara ^b   Schwarzwald, Heidi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b National Hansen Disease Programs   (United States)

Author keywords

Children; Hansen disease; International adoption; Leprosy

Indexed keywords

CLOFAZIMINE; DAPSONE; PREDNISONE; RIFAMPICIN; ANTIINFLAMMATORY AGENT; LEPROSTATIC AGENT;

ADOPTION; ARTICLE; CASE REPORT; CHILD; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; ETHIOPIA; FEMALE; GRANULOMATOUS INFLAMMATION; HUMAN; HYPESTHESIA; HYPOPIGMENTATION; IMMUNE RESPONSE; LEPROSY; MULTIBACILLARY LEPROSY; PAPULE; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNITED STATES; ETHNOLOGY; MICROBIOLOGY;

ADOPTION; ANTI-INFLAMMATORY AGENTS; CHILD; ETHIOPIA; FEMALE; HUMANS; LEPROSTATIC AGENTS; LEPROSY; PREDNISONE;

EID: 65649107294     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31818de21e     Document Type: Article

References (15)

1. Lewis et al. Leprosy. Emedicine. Available at: http://www.emedicine.com/ derm/TOPIC223.HTM. Accessed May 5, 2008.
2. World Health Organization web site. Available at: http://www.who.int/lep. Accessed May 5, 2008.
3. Summary of Reportable Diseases, 2006. MMWR. 2008;55:1-94.
4. Britton WJ, Lockwood DNJ. Leprosy. Lancet. 2004;363:1209 -1219.
5. Federal Ministry of Health Ethiopia. Strategic Plan 2007/8 -2009/10 TB and Leprosy Control Program. Addis Abba, Ethiopia: Federal Ministry of Health Ethiopia; 2007:1-79.
6. John TJ, Muliyil J. Care after cure in leprosy. Lancet. 2001;357:313.
7. Chen XS, Li WZ, Jiang C, et al. Leprosy in children: a retrospective study in China, 1986-1997. J Trop Pediatr. 2000;46:207-211.
8. Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from North India. Int J Lepr Other Mycobact Dis. 2004;72:125-133.
9. Scollard DM, Adams LB, Gillis TP, et al. The continuing challenges of leprosy. Clin Microbiol Rev. 2006;19:338 -381.
10. Martiniuk F, Rao SD, Rea TH, et al. Leprosy as immune reconstitution inflammatory syndrome in HIV-positive persons. Emerg Infect Dis. 2007; 13:1438 -1439.
11. Scollard DM, Joyce MP, Gillis TP. Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of two cases. Clin Infect Dis. 2006;43:e19-e22.
12. Bochud PY, Hawn TR, Siddiqui MR, et al. Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Inf Dis. 2008;197:253-261.
13. Biosca G, Casallo S, Lopez-Velez R. Methotrexate treatment for type 1 (reversal) leprosy reactions. Clin Infect Dis. 2007;45:e7- e9.
14. Cuevas J, Rodriguez-Peralto JL, Carrillo R, et al. Erythema nodosum leprosum: reactional leprosy. Semin Cutan Med Surg. 2007; 26:126 -130.
15. WHO Leprosy Unit. Risk of relapse in leprosy. Indian J Lepr. 1995; 67:13-26.